Olaparib: tested in a combination
175 studies: another drug in the study is under test too. Page 2 of 2. Open to participants first (41), then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).Status unknownNCT05201612Phase 2Report a problem
- The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene MutationStatus unknownNCT05167175Phase 2Report a problem
- Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2Report a problem
- A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial CarcinosarcomaCompletedNCT05156268Phase 2Report a problem
- Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerActive, not recruitingNCT05093231Phase 2Report a problem
- Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDOActive, not recruitingNCT05033756Phase 2Report a problem
- Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer SubjectsCompletedNCT04939662Phase 2Report a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2Report a problem
- Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal CancerActive, not recruitingNCT04825990Phase 2Report a problem
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicableReport a problem
- Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)Active, not recruitingNCT04748042Phase 2Report a problem
- Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO TrialActive, not recruitingNCT04728230Phase 1/2Report a problem
- Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesActive, not recruitingNCT04711824Phase 1/2Report a problem
- A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based TherapyActive, not recruitingNCT04666740Phase 2Report a problem
- Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04644432Phase 2Report a problem
- Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical CancerStatus unknownNCT04641728Phase 2Report a problem
- Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) MutationStatus unknownNCT04633902Phase 2Report a problem
- Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Phase 3Report a problem
- Study of Pamiparib in Newly Diagnosed and rGBMCompletedNCT04614909Early Phase 1Report a problem
- Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2Report a problem
- Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3Report a problem
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursCompletedNCT04375267Phase 1Report a problem
- Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian CancerStatus unknownNCT04361370Phase 2Report a problem
- Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.Active, not recruitingNCT04348045Phase 2Report a problem
- NUVOLA TRIAL Open-label Multicentre StudyStatus unknownNCT04261465Phase 2Report a problem
- A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnNCT04239014Phase 2Report a problem
- Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)CompletedNCT04123366Phase 2Report a problem
- Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2Report a problem
- Tri Association in Patient With Advanced Epithelial Ovarian Cancer in RelapseStatus unknownNCT04015739Phase 2Report a problem
- Study of Olaparib and Durvalumab in IDH-Mutated Solid TumorsActive, not recruitingNCT03991832Phase 2Report a problem
- Durvalumab and Olaparib in Metastatic or Recurrent Endometrial CancerStatus unknownNCT03951415Phase 2Report a problem
- Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast CancerTerminatedNCT03931551Phase 2Report a problem
- Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerActive, not recruitingNCT03923270Phase 1Report a problem
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT03874884Phase 1Report a problem
- Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingNCT03851614Phase 2Report a problem
- Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.CompletedNCT03838744Phase 2Report a problem
- Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerActive, not recruitingNCT03742245Phase 1Report a problem
- An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Status unknownNCT03699449Phase 2Report a problem
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1Report a problem
- Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerActive, not recruitingNCT03594396Phase 1/2Report a problem
- Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerActive, not recruitingNCT03579784Phase 2Report a problem
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2Report a problem
- A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.CompletedNCT03553108Phase 1Report a problem
- Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerCompletedNCT03544125Phase 1Report a problem
- Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)CompletedNCT03534492Phase 2Report a problem
- A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung CancerCompletedNCT03532880Phase 1Report a problem
- IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOCCompletedNCT03378297Early Phase 1Report a problem
- Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCCompletedNCT03263650Phase 2Report a problem
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2Report a problem
- Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas PatientsActive, not recruitingNCT03212742Phase 1/2Report a problem
- Selumetinib and Olaparib in Solid TumorsActive, not recruitingNCT03162627Phase 1Report a problem
- Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid TumorsCompletedNCT03127215Phase 2Report a problem
- Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2Report a problem
- A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).CompletedNCT03022409Phase 1Report a problem
- Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsActive, not recruitingNCT03012321Phase 2Report a problem
- Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.CompletedNCT02882308Phase 2Report a problem
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruitingNCT02861573Phase 1/2Report a problem
- Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian CancerCompletedNCT02855697Early Phase 1Report a problem
- Substantially Improving the Cure Rate of High-risk BRCA1-like Breast CancerActive, not recruitingNCT02810743Phase 3Report a problem
- Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer PatientsCompletedNCT02755844Phase 1/2Report a problem
- PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialActive, not recruitingNCT02624973Phase 2Report a problem
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior ChemotherapyStatus unknownNCT02446704Phase 1/2Report a problem
- Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced CancerCompletedNCT02418624Phase 1Report a problem
- Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck CancerCompletedNCT02308072Phase 1Report a problem
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2Report a problem
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2Report a problem
- Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid TumoursCompletedNCT01929603Phase 1Report a problem
- To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid TumoursCompletedNCT01900028Phase 1Report a problem
- Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or RhabdoomyosarcomaCompletedNCT01858168Phase 1Report a problem
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1Report a problem
- Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT01491139Phase 1Report a problem
- Olaparib and Temozolomide in Treating Patients With Relapsed GlioblastomaCompletedNCT01390571Phase 1Report a problem
- AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor CancersCompletedNCT00678132Phase 1Report a problem
- AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal CancerCompletedNCT00535353Phase 1Report a problem
- A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With DacarbazineCompletedNCT00516802Phase 1Report a problem